Acrotech Biopharma and Otsuka Pharmaceutical Receive the US FDA Approval for Adquey to Treat Mild-to-Mod. Atopic Dermatitis 

Shots: 

• The US FDA has approved Adquey (difamilast 1%) ointment for treating mild-to-mod. atopic dermatitis in adults and children aged≥ 2 yrs. 

• Approval was based on multiple pivotal P-III trials, which showed a significantly higher proportion of patients treated with ADQUEY achieving IGA success after 4 wks vs vehicle, with a consistent safety profile 

• Adquey is a non-steroidal topical PDE-4 inhibitor for BID treatment of mild-to-mod. atopic dermatitis in patients aged ≥2 years, inhibiting all PDE-4 subtypes. Difamilast was discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma in the U.S. in 2021 

Ref: Aurobindo | Image: Acrotech Biopharma and Otsuka Pharmaceutical |Press Release

Related News: Merck Receives the FDA Approval for Keytruda and Keytruda Qlex, Plus CT ± Avastin to Treat PD-L1+ Pt-Resistant Ovarian Carcinoma

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com